Filing Details

Accession Number:
0001209191-21-046028
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-08 18:15:57
Reporting Period:
2021-07-06
Accepted Time:
2021-07-08 18:15:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576885 Acumen Pharmaceuticals Inc. ABOS Biological Products, (No Disgnostic Substances) (2836) 364108129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1804350 D. Robert Hardie C/o Acumen Pharmaceuticals, Inc.
427 Park Street
Charlottesville VA 22902
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-06 2,950,484 $0.00 3,040,193 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-07-06 312,500 $16.00 3,352,693 No 4 P Indirect See footnote
Common Stock Acquisiton 2021-07-06 657,985 $0.00 657,985 No 4 C Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 C Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Preferred Stock Disposition 2021-07-06 1,634,515 $0.00 1,634,515 $0.00
Common Stock Series B Preferred Stock Disposition 2021-07-06 1,315,969 $0.00 1,315,969 $0.00
Common Stock Series B Preferred Stock Disposition 2021-07-06 657,985 $0.00 657,985 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "PreferredStock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering ofthe Issuer's common stock. The shares had no expiration date.
  2. The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
  3. The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, themanager of BKB, and has shared voting and investment power with respect to the shares held by BKB.